Replies to post #214975 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Probably $50B.

[abeta]

What is her number?

hyper - you can help her -

(a) $125,000 TIMES

(b) # LUNG cancer patients

ADDED TO

(a) $125,000 TIMES

(b) # COLON cancer patients

ADDED TO

(a) $125,000 TIMES

(b) # SARCOMA cancer patients

ADDED TO

(a) $125,000 TIMES

(b) # OVARIAN cancer patients

ADDED TO

(a) $125,000 TIMES

(b) # PANCREATIC cancer patients

ADDED TO

(a) $125,000 TIMES

(b) # GBM cancer patients

ADDED TO

(a) $125,000 TIMES

(b) # MELANOMA cancer patients


Take the SUM of the above AND multiply it

by 12

OR

by 11

OR

by 10

That is your POTENTIAL MARKET CAP.

But - she already knows this.

And - I disagree with you - we are NOT that far away -
DCVAX-L approval will speed things along ....

regards

[photonic5]

The KITE and JUNO valuations are what make valuing a positive P3 trial here tricky. Both were valued at $10-$15 billion, but didn’t have as much potential as a successfully demonstrated DCVAX platform. The question really becomes, what would that be worth? I think the value starts at $20-$25 billion. I think DCVAX-L alone is worth $10-$15 billion after a successful P3 trial. There are going to be all sorts of calls to expand use with no side effects, if efficacy is demonstrated on solid tumors.